Differentiating Thrombotic Microangiopathies in Children: Diagnostic Challenges and Therapeutic Insights

Abstract

Thrombotic microangiopathies (TMAs) represent a diverse group of disorders characterized by microvascular thrombosis, hemolytic anemia, and organ dysfunction. In children, the differentiation of TMAs is critical due to their overlapping clinical presentations and distinct therapeutic implications. This review explores the key diagnostic criteria, etiological factors, and pathophysiological mechanisms underlying pediatric TMAs, including hemolytic uremic syndrome (HUS), thrombotic thrombocytopenic purpura (TTP), and secondary TMAs associated with infections, malignancies, or autoimmune conditions. We emphasize the role of advanced diagnostic tools, such as genetic and complement pathway analyses, and highlight emerging biomarkers for improved classification. Furthermore, therapeutic strategies, ranging from plasma exchange to complement inhibitors, are discussed in the context of recent clinical advances. By elucidating the nuances in TMA subtypes, this review aims to guide clinicians and researchers toward timely, targeted interventions that improve outcomes in affected children.